New hope for half of IBD patients who Don't respond to current treatments
NCT ID NCT07184138
Summary
This study aims to see how well a newer class of drugs, called IL-23 inhibitors, works for Chinese adults with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. It will follow 178 patients in real-world clinics for one year to check if the drugs help control their disease and are safe. The goal is to gather evidence on these treatments specifically for patients in China.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMATORY BOWEL DISEASE (CROHN'S AND ULCERATIVE COLITIS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.